The European Medicines Agency and the US Food and Drug Administration announced their individual regulatory decisions and resulting actions regarding the marketing of GlaxoSmithKline's (London) Avandia (rosiglitazone), a thiazolidinedione used to treat Type 2 diabetes.
Novartis Sells US Enablex Rights; Ricerca Names Chemistry Director; And More.
DSM and PolyTherics in Development Deal; Kite Pharma Appoints President and CEO, And More.
Johnson & Johnson (J&J, New Brunswick, NJ) announced last week that it was in "advanced negotiations" for a potential public offer for the Dutch biopharmaceutical company Crucell (Leiden, The Netherlands).
Genzyme Sells Genetics Business; Bausch and Lomb Names Vice-President; and More.
Bristol-Myers Squibb (New York) has agreed to acquire the biopharmaceutical company ZymoGenetics (Seattle) for an aggregate purchase price of $885 million or $735 million net of cash.
The generic-drug company Actavis (Hafnarfjordur, Iceland) is considering acquiring a 51% stake in the biopharmaceutical company BioPartners Holdings (Barr, Switzerland) from Bioton, a Polish biotechnology company.
Pfizer to Acquire FoldRx; Protalix Appoints COO; And More.
The Society for Chemical Manufacturers and Affiliates (SOCMA) issued recommendations relating to disclosure of confidential business information (CBI) in response to Environmental Protection Agency's (EPA) decision to limit CBI claims on chemical identity under the Toxic Substances Control Act (TSCA).
Company and People Notes: Lonza Acquired Vivante; PPD Appoints VP of Quality Management; And More.
A look at why Brazil revised its GMP standards and how the changes will affect the local pharmaceutical industry.
Pharmaceutical Technology gains insight into approaches for producing aromatic amines.
New data provide insight into pharma-industry professionals' daily lives.
The current trend in the pharmaceutical industry for the manufacture of small-molecule therapeutic agents is moving toward continuous flow processes. This article is part of a special issue on APIs.
The author presents recent developments in simulated moving-bed chromatography in production of active pharmaceutical ingredients and intermediates. This article is part of a special issue on APIs.
The author explains the background behind the excipient pedigree and how to implement its use.
The authors discuss a continuous-flow reactor that avoids parallel channels and enables economic plant setup. This article is part of a special issue on API Development, Formulation, Synthesis and Manufacturing.
The authors discuss the capabilities of immobilization technologies and the ability to use an expanded range of solvents for mobile-phase components and solvent dissolutions. This article is part of a special issue on APIs.
The authors describe several examples of using asymmetric hydrogenation and biocatalysis for synthesizing several secondary alcohol compounds.
Week of Aug. 23, 2010: Company and People Notes: Quark and Novartis Form Agreement; Hospira CEO Retires; And More.
Eli Lilly Ends Semagacestat Program; Selecta Appoints CEO; And More.
Making highly potent active pharmaceutical ingredients (HPAPIs) can be costly because the process often requires equipment specialized to achieve containment and extra attention to safety concerns. Pharmaceutical professionals may wonder whether disposable components, which have reduced the cost of some operations, might be appropriate in the manufacture of HPAPIs.
Sen. Michael Bennet (D-CO) introduced a bill earlier this month, the Drug Safety and Accountability Act of 2010, which is designed to improve regulatory oversight of drug-manufacturing facilities and improve related quality standards and monitoring.
Penwest and Endo to Merge; Watson Makes Senior Appointments; And More.
